Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Leukemia
CAR T-Cell Therapy Augments Response to Ibrutinib in Chronic Lymphocytic Leukemia
By
Phoebe Starr
Leukemia
,
Hematologic Malignancies
June 2019, Vol 10, No 3
San Diego, CA—Results with chimeric antigen receptor (CAR) T-cell therapy have been less robust in chronic lymphocytic leukemia (CLL) compared with B-cell acute lymphocytic leukemia and diffuse large B-cell lymphoma. Preliminary studies presented at ASH 2018 suggested that a strategy of using CAR T-cell therapy to augment the response to ibrutinib (Imbruvica) holds promise in patients with CLL.
Read Article
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
By
Wayne Kuznar
2019 NCCN Conference
,
Leukemia
,
Hematologic Malignancies
April 2019, Vol 10, No 2
Orlando, FL—The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.
Read Article
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
By
Wayne Kuznar
Immunotherapy
,
Leukemia
,
Lymphoma
,
Hematologic Malignancies
,
Personalized Medicine
April 2019, Vol 10, No 2
San Francisco, CA—Many patients with leukemia or lymphoma who receive treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieve minimum residual disease (MRD) negativity, and many are in complete remission well beyond 12 months.
Read Article
Adding Pegylated Interferon to Nilotinib Enhances Molecular Response in Chronic-Phase Chronic Myeloid Leukemia
By
Wayne Kuznar
Leukemia
,
FDA Approvals, News & Updates
,
Hematologic Malignancies
Web Exclusives
Read Article
Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia
By
Chase Doyle
Leukemia
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—A chimeric antigen receptor (CAR) T-cell therapy that targets CD19 and CD22 molecules has demonstrated safety and efficacy, in patients with relapsed or refractory B-cell precursor acute lymphoblastic lymphoma (ALL), with response rates consistent with CAR T-cell therapies that target CD19 alone.
Read Article
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL
By
Phoebe Starr
Leukemia
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—A 2-year duration of combination immunotherapy with venetoclax (Venclexta) and rituximab (Rituxan) improved survival compared with standard-of-care chemoimmunotherapy combination with bendamustine (Bendeka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to follow-up data from the MURANO clinical trial presented at ASH 2018. Early results were first presented at ASH 2017.
Read Article
Researchers Identify First Mutation to Explain Resistance to Venetoclax
By
Phoebe Starr
Leukemia
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—The
BCL2 Gly101Val
mutation is the first genomic alteration to be identified as responsible for resistance to venetoclax (Venclexta), a potent and effective medication indicated for the treatment of chronic lymphocytic leukemia (CLL). The
BCL2 Gly101Val
mutation is unique to CLL and so far has not been described in other cancers.
Read Article
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation
By
Charles Bankhead
Leukemia
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—More than 40% of older patients with acute myeloid leukemia (AML) associated with an
IDH2
mutation achieved complete remission when treated with the
IDH2
inhibitor enasidenib (Idhifa), according to results of a mutation-driven clinical trial substudy presented at ASH 2018.
Read Article
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
By
Wayne Kuznar
Leukemia
,
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—Front-line ibrutinib (Imbruvica) therapy results in a lower rate of disease progression or death than the current standard-of-care chemoimmunotherapy with bendamustine (Bendeka) and rituximab (Rituxan) in older patients with chronic lymphocytic leukemia (CLL). Adding rituximab to ibrutinib did not improve outcomes compared with ibrutinib alone, reported Jennifer A. Woyach, MD, Associate Professor, Ohio State University Comprehensive Cancer Center, Columbus, at ASH 2018.
Read Article
Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL
Hematologic Malignancies
,
In the Literature
,
Leukemia
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Chemoimmunotherapy with chlorambucil plus obinutuzumab or bendamustine plus rituximab is standard frontline treatment for older patients with chronic lymphocytic leukemia (CLL). However, chemoimmunotherapy is associated with toxic effects, and the risk increases with age.
Read Article
Page 4 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma